Thursday May 25th 2017

Archive for March, 2014

Mp17-08 neurogenic bladder dysfunction in a murine model of multiple sclerosis is caused by coronovirus-induced demyelination of the nervous system

Mp17-08 neurogenic bladder dysfunction in a murine model of multiple sclerosis is caused by coronovirus-induced demyelination of the nervous system

(Source: The Journal of Urology)MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here. [Read More]

Mp80-08 urologic barriers to care in patients with multiple sclerosis

Mp80-08 urologic barriers to care in patients with multiple sclerosis

(Source: The Journal of Urology) [Read More]

 Page 1 of 90  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]